Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 535.00K | 582.00K | 598.00K | 162.00K | 115.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 535.00K | 582.00K | 598.00K | 162.00K | 115.00K |
| Cost of Revenue | 35.00K | 96.00K | 162.00K | 342.00K | 247.00K |
| Gross Profit | 500.00K | 486.00K | 436.00K | -180.00K | -132.00K |
| SG&A Expenses | 10.43M | 13.32M | 16.13M | 16.80M | 15.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.73M | 17.83M | 20.92M | 22.15M | 21.26M |
| Operating Income | -14.19M | -17.25M | -20.32M | -21.99M | -21.15M |
| Income Before Tax | -46.06M | -44.51M | -44.92M | -23.93M | -22.90M |
| Income Tax Expenses | 34.00K | 30.00K | 15.00K | -5.00K | -4.00K |
| Earnings from Continuing Operations | -46.09 | -44.54 | -44.93 | -23.92 | -22.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.09M | -44.54M | -44.93M | -23.92M | -22.90M |
| EBIT | -14.19M | -17.25M | -20.32M | -21.99M | -21.15M |
| EBITDA | -14.08M | -17.11M | -20.18M | -21.86M | -21.04M |
| EPS Basic | -93.68 | -109.80 | -124.62 | -66.36 | -63.78 |
| Normalized Basic EPS | -22.71 | -32.78 | -41.79 | -41.57 | -39.22 |
| EPS Diluted | -93.68 | -109.80 | -124.62 | -66.36 | -63.78 |
| Normalized Diluted EPS | -22.71 | -32.78 | -41.79 | -41.57 | -39.22 |
| Average Basic Shares Outstanding | 6.84M | 3.64M | 1.44M | 1.44M | 1.44M |
| Average Diluted Shares Outstanding | 6.84M | 3.64M | 1.44M | 1.44M | 1.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.02% | -0.02% | -0.04% | -0.07% | -0.07% |